Home  |  Contact

Cellosaurus IHH-4 (CVCL_2960)

Cell line name IHH-4
Synonyms IHH4
Accession CVCL_2960
Resource Identification Initiative To cite this cell line use: IHH-4 (RRID:CVCL_2960)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Doubling time: 42 hours (PubMed=11686581).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations AKT1 p.Glu17Lys (c.49G>A) (PubMed=23833040).
BRAF p.Val600Glu (c.1799T>A) (PubMed=23833040).
Heterozygous for TERT c.228C>T (-124C>T); in promoter (PubMed=23833040).
Disease Thyroid gland papillary carcinoma (NCIt: C4035)
Derived from metastatic site: Left cervical lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_3219 (TMH-1)
Sex of cell Male
Age at sampling 75Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; JCRB

Markers:
AmelogeninX,Y
CSF1PO12
D13S31710,13
D16S5399,11
D5S8189,13
D7S8209,10
TH019
TPOX11
vWA16,18
Publications

PubMed=11686581; DOI=10.1016/S0753-3322(01)00087-7
Sekiguchi M., Shiroko Y., Arai T., Kishino T., Sugawara I., Kusakabe T., Suzuki T., Yamashita T., Obara T., Ito K., Hasumi K.
Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines.
Biomed. Pharmacother. 55:466-474(2001)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections JCRB; JCRB1079
JCRB; NIHS0270 - Discontinued
JCRB; NIHS0270.1 - Discontinued
JCRB; NIHS0271.1 - Discontinued
Cell line databases/resources CCLE; IHH4_THYROID
Cosmic-CLP; 1240154
GDSC; 1240154
LINCS_LDP; LCL-1693
Biological sample resources BioSample; SAMN03481111
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM827172
GEO; GSM1669931
Other Wikidata; Q54897412
Polymorphism and mutation databases Cosmic; 1995454
Cosmic; 2054088